Squadron Capital Management’s Silence Therapeutics SLN Stock Holding History
Bought
Maintained
Sold
Other funds holding SLN
SL
Squadron Capital Management's SLN Position: Q3 2026 in Review
Squadron Capital Management opened a new position in Silence Therapeutics (SLN) in Q3 2026: 2,085,000 shares worth $22.8M. The stake represents 5.72% of the portfolio and ranks #5 among its holdings.
92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.
- Squadron Capital Management held 2,085,000 shares of Silence Therapeutics worth $22.8M as of Q3 2026.
- Silence Therapeutics was a new Squadron Capital Management position in Q3 2026.
- Silence Therapeutics made up 5.72% of Squadron Capital Management's portfolio in Q3 2026, its #5 holding.
- 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.
Based on Squadron Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.